Navigation Links
Insmed Announces First Quarter 2011 Financial Results
Date:5/10/2011

delays in our product development or clinical trials, our product candidates may not prove to be commercially successful, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2010.  Investors are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.INSMED INCORPORATEDConsolidated Balance Sheets (Unaudited)(in thousands, except share and per share data)March 31,December 31,20112010AssetsCurrent assets:  Cash and cash equivalents $
22,100$
,743  Short-term investments80,62497,306  Accounts receivable, net169471  Prepaid expenses169277Total current assets103,062108,797Certificate of deposit 2,1762,176In-process research and development77,90077,900Goodwill6,2906,290Fixed assets, net1,0421,102Total assets$
90,470$
96,265Liabilities and stockholders' equityCurrent liabilities:  Accounts payable $
3,082$
,450  Accrued expenses9151,256  Deferred rent150150  Capital lease obligations, current7281  Deferred revenue244402Total current liabilities4,4633,339Restricted stock units compensation liability132-Capital lease obligations, long-term7183Total liabilities4,6663,422Stockholders' equity:Common stock; $.01 par value; authorized shares500,000,000; issued and outstanding shares, 24,828,101 in 2011 and 15,653,734 in 20102481,565Preferred stock; $.01 par value; authorized shares200,000,000; issued and outstanding shares, zero in 2011 and 9,174,589 in 2010-918  Additional paid-in capital426,146423,877  Accumula
'/>"/>
SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Insmed to Host 2011 First Quarter Earnings Conference Call
2. Insmed Announces European Medicines Agency Acceptance of Its Pediatric Investigation Plan for ARIKACE™ in the Cystic Fibrosis Pseudomonas Indication
3. One-for-10 Reverse Stock Split of Insmed Common Stock Becomes Effective
4. Insmed Shareholders Approve Conversion of Series B Conditional Convertible Preferred Stock and Reverse Stock Split
5. Insmed to Host Fourth Quarter and 2010 Year-End Earnings Conference Call
6. NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule
7. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2010
8. Insmed to Host Third Quarter 2010 Conference Call
9. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
10. Insmed CEO to Present at Congressional Briefing on Follow-On Biologics
11. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
(Date:1/15/2014)... Medical is very pleased to announce the appointment of Mr. ... Officer.  Mark was promoted from his current role of Chief ... facilities in Massachusetts , Mississippi ... in 2012 with 20+ years of broad-based operations, sales, engineering ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Mich. , May 19 Stryker Corporation (NYSE: ... has informed the Company that the actions undertaken to address issues raised ... , , , ... Warning Letter from FDA regarding compliance with certain quality system requirements at ...
... SAN FRANCISCO, Calif. , May 19 ... studies was published in The Lancet on ... elevated levels of lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific ... coronary heart disease similar in magnitude to that with ...
Cached Medicine Technology:Stryker Announces Resolution of Two FDA Warning Letters 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 2Large Meta-Analysis Further Validates Benefit of Measuring Lp-PLA2 for Coronary Heart Disease and Ischemic Stroke Risk Assessment 3
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... Calif., April 17, 2014 By discovering a new ... after a stroke, researchers at UC Irvine and the ... that may limit or prevent stroke-induced brain damage. , ... fourth-leading cause of death and primary reason for disability ... in a stroke and lets blood-borne material into the ...
(Date:4/17/2014)... online has the potential to ward off depression among ... research published online in The Journals of ... . In the article " Internet Use and Depression ... Longitudinal Analysis ," the authors report that Internet use ... percent among their study sample. , Late-life depression ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2Health News:Internet use may cut retirees' depression 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... Yarl’s Wood one of the country's biggest immigration detention ... long-term detainees, according to the report of the prison ... launched an inquiry into healthcare at Yarl's Wood Immigration ... treatment of two female asylum seekers from Uganda. ...
... A ban on smoking cigarettes in public places such as ... recommendation// made by a panel consisting of members from the ... that about 3000 to 5000 people exposed to passive smoking ... However a statutory ban on smoking in France could trigger ...
... introduced a new medical device to facilitate the ... ,The Cuban-made equipment, Digital ANGIODIN PD-3000 ... dysfunction and micro and macro vessel failures at ... Tuesday. ,The equipment is simple in ...
... Nobel prize for medicine has been conferred on two Americans, ... of the Harvard University//, for their discovery of ‘RNA interference’, ... humans. , ‘RNA interference’ involves the silencing ... role in the regulation of gene expression, controls the activity ...
... announced on Tuesday the acquisition of Pinewood Laboratories// Limited ... broaden its presence in the European market. ,'This ... over Britain, Ireland and Germany,' Wockhardt chairman Habil Khorakiwala ... million, accounting for almost half of Wockhardt's total sales,' ...
... after the devastating earthquake of 8 October 2005 in ... at risk, facing a second winter without permanent shelter.// ... left around 3.5 million homeless. Estimates have shown that ... while recent landslides and flooding have left most quake ...
Cached Medicine News:Health News:Nobel Prize for Gene ‘Silencing 2Health News:Survivors of Pakistan Earthquake Still at Risk 2
For use under silicone strips E5381 610, E5381 611 and E5381 710. Indications: When higher buckle is required. Overall length: 6.1 mm....
Ungrooved permanent silicone strip. Indications: For trapdoor procedure. Overall length: 125 mm, 4.9 inches....
Used with Double Tantalum Clip (250 style) E5381 852. Overall length: 7.0 mm....
Our largest silicone tire with concave inner surface. Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Massive breaks covering large areas. Outside diameter 31.7 mm....
Medicine Products: